Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

Benralizumab is marketed under the trade ... “The OSTRO results show that Fasenra’s eosinophil-depleting mechanism of action may benefit patients with this often debilitating condition ...

“Based on [benralizumab’s] eosinophil-depleting mechanism of action, we’re hopeful it can help address these unmet needs and improve patient outcomes,” said Mene Pangalos, Executive Vice ...

FASENRA FASENRA (benralizumab) is currently approved as an add-on maintenance treatment for SEA in the US, EU, Japan and other countries, and is approved for self-administration in the US, EU and ...

Moreover, the biologics that are available have different mechanisms of action, ... Dupilumab, benralizumab, and mepolizumab were compared in patients with ≥2 pre-index exacerbations.

Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed ...

The US Food and Drug Administration (FDA) has approved benralizumab (Fasenra) for the treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss ...

AstraZeneca's respiratory candidate benralizumab can help some severe asthma patients cut down on—or even stop—the unsavory steroid pills they use daily to stave off attacks, a new study showed ...